KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Income from Continuing Operations (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Income from Continuing Operations for 8 consecutive years, with 62597000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 400.34% year-over-year to 62597000.0, compared with a TTM value of 24331000.0 through Dec 2025, down 401.77%, and an annual FY2025 reading of 22682000.0, up 56.17% over the prior year.
  • Income from Continuing Operations was 62597000.0 for Q4 2025 at Esperion Therapeutics, up from 32010000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 62597000.0 in Q4 2025 and bottomed at 90949000.0 in Q1 2021.
  • Average Income from Continuing Operations over 5 years is 37655650.0, with a median of 47636000.0 recorded in 2021.
  • Peak annual rise in Income from Continuing Operations hit 400.34% in 2025, while the deepest fall reached 171.3% in 2025.
  • Year by year, Income from Continuing Operations stood at 69058000.0 in 2021, then rose by 17.69% to 56842000.0 in 2022, then decreased by 1.02% to 57424000.0 in 2023, then skyrocketed by 63.71% to 20842000.0 in 2024, then surged by 400.34% to 62597000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for ESPR at 62597000.0 in Q4 2025, 32010000.0 in Q3 2025, and 13391000.0 in Q2 2025.